PT3310909T - Composições e métodos para dirigir proteínas para loci específicos no genoma - Google Patents
Composições e métodos para dirigir proteínas para loci específicos no genomaInfo
- Publication number
- PT3310909T PT3310909T PT167338136T PT16733813T PT3310909T PT 3310909 T PT3310909 T PT 3310909T PT 167338136 T PT167338136 T PT 167338136T PT 16733813 T PT16733813 T PT 16733813T PT 3310909 T PT3310909 T PT 3310909T
- Authority
- PT
- Portugal
- Prior art keywords
- compositions
- methods
- specific loci
- genome specific
- directing proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562181162P | 2015-06-17 | 2015-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3310909T true PT3310909T (pt) | 2021-09-09 |
Family
ID=56292934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167338136T PT3310909T (pt) | 2015-06-17 | 2016-06-16 | Composições e métodos para dirigir proteínas para loci específicos no genoma |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11473082B2 (enExample) |
| EP (2) | EP3310909B1 (enExample) |
| JP (3) | JP2018521689A (enExample) |
| KR (1) | KR102637402B1 (enExample) |
| CN (1) | CN108026519A (enExample) |
| AU (2) | AU2016278226B2 (enExample) |
| CA (1) | CA2989827C (enExample) |
| DK (1) | DK3310909T3 (enExample) |
| ES (1) | ES2886599T3 (enExample) |
| PT (1) | PT3310909T (enExample) |
| WO (1) | WO2016205554A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2778033T3 (es) | 2012-11-16 | 2020-08-07 | Poseida Therapeutics Inc | Enzimas específicas de sitio y métodos de uso |
| KR102630014B1 (ko) | 2014-10-01 | 2024-01-25 | 더 제너럴 하스피탈 코포레이션 | 뉴클레아제-유도 상동성-지정 복구의 효율 증가 방법 |
| US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| KR102588469B1 (ko) * | 2016-09-30 | 2023-10-11 | 포세이다 테라퓨틱스, 인크. | 변형된 줄기세포 기억 t 세포, 이의 제조 방법 및 사용 방법 |
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| JP7275043B2 (ja) | 2016-12-16 | 2023-05-17 | ビー－モーゲン・バイオテクノロジーズ，インコーポレーテッド | 増大したｈＡＴファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法 |
| SG10202109731YA (en) | 2017-03-13 | 2021-10-28 | Poseida Therapeutics Inc | Compositions and methods for selective elimination and replacement of hematopoietic stem cells |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| AU2018299995B2 (en) * | 2017-07-11 | 2021-10-28 | Sigma-Aldrich Co. Llc | Using nucleosome interacting protein domains to enhance targeted genome modification |
| US12227742B2 (en) | 2017-10-23 | 2025-02-18 | The Broad Institute, Inc. | Nucleic acid modifiers |
| US10329543B2 (en) | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
| WO2019126578A1 (en) * | 2017-12-20 | 2019-06-27 | Poseida Therapeutics, Inc. | Compositions and methods for directing proteins to specific loci in the genome |
| WO2019246486A2 (en) | 2018-06-21 | 2019-12-26 | B-Mogen Biotechnologies, Inc. | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
| CN110938658B (zh) * | 2018-09-21 | 2023-02-07 | 中国科学院分子细胞科学卓越创新中心 | 一种抗体进化方法及其应用 |
| WO2020077360A1 (en) | 2018-10-12 | 2020-04-16 | Poseida Therapeutics, Inc. | Hematopoietic stem cell compositions, methods of making and method of use |
| CN113498439A (zh) | 2018-12-20 | 2021-10-12 | 波赛达治疗公司 | 纳米转座子组合物及使用方法 |
| WO2020160481A1 (en) * | 2019-02-01 | 2020-08-06 | The General Hospital Corporation | Targetable 3'-overhang nuclease fusion proteins |
| US20220204569A1 (en) * | 2019-04-09 | 2022-06-30 | Japan Science And Technology Agency | Nucleic acid-binding protein |
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| AU2020342544A1 (en) | 2019-09-05 | 2022-03-24 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
| CN115135672A (zh) | 2019-12-20 | 2022-09-30 | 波赛达治疗公司 | 抗muc1组合物和使用方法 |
| US20230121433A1 (en) | 2020-03-11 | 2023-04-20 | Poseida Therapeutics, Inc. | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation |
| CN116670154A (zh) | 2020-07-24 | 2023-08-29 | 总医院公司 | 增强的病毒样颗粒及使用其递送至细胞的方法 |
| WO2022087148A1 (en) | 2020-10-21 | 2022-04-28 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
| WO2022087354A1 (en) * | 2020-10-23 | 2022-04-28 | Altius Institute For Biomedical Sciences | Cell permeable proteins for genome engineering |
| CN112750498B (zh) * | 2020-12-30 | 2022-06-24 | 同济大学 | 靶向逆转录引物结合位点从而抑制hiv病毒复制的方法 |
| US20240060090A1 (en) | 2021-02-23 | 2024-02-22 | Poseida Therapeutics, Inc. | Genetically modified induced pluripotent stem cells and methods of use thereof |
| EP4297728A1 (en) | 2021-02-23 | 2024-01-03 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
| US20240424097A1 (en) | 2021-09-09 | 2024-12-26 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
| AU2022360244A1 (en) | 2021-10-04 | 2024-04-11 | Poseida Therapeutics, Inc. | Transposon compositions and methods of use thereof |
| US20250099383A1 (en) | 2022-01-21 | 2025-03-27 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
| WO2023164573A1 (en) * | 2022-02-23 | 2023-08-31 | Poseida Therapeutics, Inc. | Genetically modified cells and methods of use thereof |
| WO2023209649A1 (en) * | 2022-04-29 | 2023-11-02 | Seqirus, Inc. | Method of dna linearization |
| WO2024007010A2 (en) * | 2022-06-30 | 2024-01-04 | Demeetra Agbio, Inc. | Gene editing compositions and methods of use thereof |
| EP4605525A1 (en) | 2022-10-21 | 2025-08-27 | Keygene N.V. | Rna transfection in plant cells with modified rna |
| CN120225666A (zh) | 2022-11-21 | 2025-06-27 | 艾欧凡斯生物治疗公司 | 用于评估基因编辑的t细胞的增殖效力的方法 |
| EP4623072A2 (en) | 2022-11-21 | 2025-10-01 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| WO2024121354A1 (en) | 2022-12-08 | 2024-06-13 | Keygene N.V. | Duplex sequencing with covalently closed dna ends |
| EP4651943A1 (en) | 2023-01-20 | 2025-11-26 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| IL322198A (en) | 2023-01-20 | 2025-09-01 | Poseida Therapeutics Inc | Lipidoid compounds and related compositions and uses |
| CN121079405A (zh) * | 2023-02-21 | 2025-12-05 | 波西达治疗公司 | 用于基因组编辑的组合物和方法 |
| EP4669745A1 (en) * | 2023-02-21 | 2025-12-31 | Poseida Therapeutics, Inc. | COMPOSITIONS AND GENOMIC EDITING PROCESSES |
| WO2024209000A1 (en) | 2023-04-04 | 2024-10-10 | Keygene N.V. | Linkers for duplex sequencing |
| AU2024271748A1 (en) | 2023-05-17 | 2025-11-13 | Poseida Therapeutics, Inc. | Compositions targeting hbg1 and hbg2 and methods of use thereof |
| WO2025049925A2 (en) | 2023-09-01 | 2025-03-06 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| WO2025096980A1 (en) | 2023-11-02 | 2025-05-08 | Poseida Therapeutics, Inc. | Compositions targeting klkb1 and methods of use thereof |
| WO2025160432A1 (en) | 2024-01-26 | 2025-07-31 | Poseida Therapeutics, Inc. | Methods and compositions for enhancing in vivo persistence and potency of cell therapy |
| WO2025171237A1 (en) | 2024-02-08 | 2025-08-14 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| WO2025221789A1 (en) | 2024-04-16 | 2025-10-23 | Poseida Therapeutics, Inc. | Compositions and methods for use in car/tcr cell therapies |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5380831A (en) | 1986-04-04 | 1995-01-10 | Mycogen Plant Science, Inc. | Synthetic insecticidal crystal protein gene |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5529774A (en) | 1991-08-13 | 1996-06-25 | The Regents Of The University Of California | In vivo transfer of the HSV-TK gene implanted retroviral producer cells |
| NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| TW261517B (enExample) | 1991-11-29 | 1995-11-01 | Mitsubishi Shozi Kk | |
| US5911983A (en) | 1992-06-26 | 1999-06-15 | University Of Pittsburgh | Gene therapy for Gaucher disease using retroviral vectors |
| US5910488A (en) | 1993-06-07 | 1999-06-08 | Vical Incorporated | Plasmids suitable for gene therapy |
| US5645829A (en) | 1993-06-18 | 1997-07-08 | Beth Israel Hospital Association | Mesothelial cell gene therapy |
| US5656465A (en) | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
| US5714353A (en) | 1994-05-24 | 1998-02-03 | Research Corporation Technologies, Inc. | Safe vectors for gene therapy |
| US5639642A (en) | 1994-06-16 | 1997-06-17 | Novo Nordisk A/S | Synthetic leader peptide sequences |
| US7285416B2 (en) | 2000-01-24 | 2007-10-23 | Gendaq Limited | Regulated gene expression in plants |
| DE19524720A1 (de) | 1995-07-12 | 1997-01-16 | Hoechst Ag | Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3" |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| JP4216350B2 (ja) | 1994-09-19 | 2009-01-28 | 大日本住友製薬株式会社 | 動物細胞感染用の組換えｄｎａウイルスベクター |
| US5789147A (en) | 1994-12-05 | 1998-08-04 | New York Blood Center, Inc. | Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood |
| US5869040A (en) | 1995-06-07 | 1999-02-09 | Biogen, Inc | Gene therapy methods and compositions |
| US5928914A (en) | 1996-06-14 | 1999-07-27 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Methods and compositions for transforming cells |
| WO2000002996A2 (en) | 1998-07-10 | 2000-01-20 | Cornell Research Foundation, Inc. | Recombinant constructs and systems for secretion of proteins via type iii secretion systems |
| CA2246005A1 (en) | 1998-10-01 | 2000-04-01 | Hsc Research And Development Limited Partnership | Hybrid genes for gene therapy in erythroid cells |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
| JP2003500051A (ja) | 1999-05-25 | 2003-01-07 | パノラマ リサーチ，インコーポレイティド | 相互作用活性化タンパク質 |
| ATE353361T1 (de) | 2000-04-28 | 2007-02-15 | Sangamo Biosciences Inc | Gezielten modifikation der chromatinstruktur |
| AU2002243645A1 (en) | 2001-01-22 | 2002-07-30 | Sangamo Biosciences, Inc. | Zinc finger proteins for dna binding and gene regulation in plants |
| US7700754B1 (en) * | 2001-06-05 | 2010-04-20 | Masahiro Hiraoka | Polypeptide for unstabilizing protein in cells under aerobic conditions and DNA encoding the same |
| US20030138850A1 (en) | 2001-10-18 | 2003-07-24 | Ekkehard Mossner | Selecting for antibody-antigen interactions in bacteria cells by employing a protein fragment complementation assay |
| US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
| WO2009095742A1 (en) | 2008-01-31 | 2009-08-06 | Cellectis | New i-crei derived single-chain meganuclease and uses thereof |
| EP1504092B2 (en) | 2002-03-21 | 2014-06-25 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
| GB0226729D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intracellular antibodies |
| US8021849B2 (en) | 2004-11-05 | 2011-09-20 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the determination of sirolimus in a sample |
| US20060252140A1 (en) | 2005-04-29 | 2006-11-09 | Yant Stephen R | Development of a transposon system for site-specific DNA integration in mammalian cells |
| US7790379B2 (en) | 2005-05-19 | 2010-09-07 | Universite De Geneve | Mapping of proteins along chromatin by chromatin cleavage |
| WO2007060495A1 (en) | 2005-10-25 | 2007-05-31 | Cellectis | I-crei homing endonuclease variants having novel cleavage specificity and use thereof |
| JP2007159512A (ja) | 2005-12-15 | 2007-06-28 | Institute Of Physical & Chemical Research | Ｉｉｓ型制限酵素を用いる翻訳終止コドンの除去方法 |
| WO2007122511A2 (en) | 2006-04-21 | 2007-11-01 | Mab-Factory Gmbh | Antibody-rnase-conjugate |
| WO2008130629A2 (en) | 2007-04-19 | 2008-10-30 | Codon Devices, Inc. | Engineered nucleases and their uses for nucleic acid assembly |
| AU2008302397A1 (en) | 2007-09-17 | 2009-03-26 | Affomix Corporation | Increasing specificity in a scFv screen using dual bait reporters |
| EP2401298A1 (en) | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Antigen-binding constructs |
| CA2751000A1 (en) | 2009-03-11 | 2010-12-23 | Wyeth Llc | Methods of purifying small modular immunopharmaceutical proteins |
| US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
| EP2571512B1 (en) | 2010-05-17 | 2017-08-23 | Sangamo BioSciences, Inc. | Novel dna-binding proteins and uses thereof |
| WO2012093833A2 (en) | 2011-01-03 | 2012-07-12 | Toolgen Incorporation | Genome engineering via designed tal effector nucleases |
| CN103328507B (zh) | 2011-01-06 | 2016-09-07 | 康普里斯股份有限公司 | Alphabody文库及其产生方法 |
| US9499592B2 (en) | 2011-01-26 | 2016-11-22 | President And Fellows Of Harvard College | Transcription activator-like effectors |
| JP5996630B2 (ja) | 2011-04-05 | 2016-09-21 | セレクティスＣｅｌｌｅｃｔｉｓ | コンパクトｔａｌｅ−ヌクレアーゼを作製する方法及びその使用 |
| EP2522726A1 (en) | 2011-05-12 | 2012-11-14 | Fundació Privada Centre de Regulació Genòmica (CRG) | Zinc finger nucleases for p53 editing |
| WO2012158986A2 (en) | 2011-05-17 | 2012-11-22 | Transposagen Biopharmaceuticals, Inc. | Methods for site-specific genetic modification in stem cells using xanthomonas tal nucleases (xtn) for the creation of model organisms |
| US20140304847A1 (en) | 2011-06-07 | 2014-10-09 | Ralf Kühn | Recombination efficiency by inhibition of nhej dna repair |
| WO2012168304A1 (en) | 2011-06-07 | 2012-12-13 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Protein having nuclease activity, fusion proteins and uses thereof |
| UA115772C2 (uk) | 2011-12-16 | 2017-12-26 | Таргітджин Байотекнолоджиз Лтд | Композиція програмованого нуклеопротеїнового молекулярного комплексу і спосіб модифікування заданої послідовності нуклеїнової кислоти-мішені |
| US20130274129A1 (en) | 2012-04-04 | 2013-10-17 | Geneart Ag | Tal-effector assembly platform, customized services, kits and assays |
| WO2013177231A1 (en) | 2012-05-21 | 2013-11-28 | Massachusetts Institute Of Technology | Translocation of non-natural chemical entities through anthrax protective antigen pore |
| MY189533A (en) * | 2012-05-25 | 2022-02-16 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| US9181535B2 (en) * | 2012-09-24 | 2015-11-10 | The Chinese University Of Hong Kong | Transcription activator-like effector nucleases (TALENs) |
| DK2911687T3 (da) | 2012-10-26 | 2019-05-13 | Univ Brussel Vrije | Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf |
| ES2778033T3 (es) | 2012-11-16 | 2020-08-07 | Poseida Therapeutics Inc | Enzimas específicas de sitio y métodos de uso |
| AU2013355214B2 (en) * | 2012-12-06 | 2017-06-15 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
| EP2931898B1 (en) | 2012-12-12 | 2016-03-09 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| US20150044772A1 (en) * | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | Crispr/cas system-based novel fusion protein and its applications in genome editing |
| SG11201609211VA (en) | 2014-03-05 | 2016-12-29 | Nat Univ Corp Univ Kobe | Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same |
| JP2017518083A (ja) | 2014-06-17 | 2017-07-06 | ポセイダ セラピューティクス， インコーポレイテッド | ｉｎ ｖｉｖｏでの非共有結合的連結のための方法および組成物 |
| JP2017518082A (ja) * | 2014-06-17 | 2017-07-06 | ポセイダ セラピューティクス， インコーポレイテッド | ゲノム中の特異的遺伝子座にタンパク質を指向させるための方法およびその使用 |
| CN104450785A (zh) * | 2014-12-08 | 2015-03-25 | 复旦大学 | 使用编码靶向核酸内切酶附着体载体的基因组编辑方法及试剂盒 |
-
2016
- 2016-06-16 DK DK16733813.6T patent/DK3310909T3/da active
- 2016-06-16 US US15/580,675 patent/US11473082B2/en active Active
- 2016-06-16 EP EP16733813.6A patent/EP3310909B1/en active Active
- 2016-06-16 ES ES16733813T patent/ES2886599T3/es active Active
- 2016-06-16 JP JP2018517674A patent/JP2018521689A/ja not_active Ceased
- 2016-06-16 CA CA2989827A patent/CA2989827C/en active Active
- 2016-06-16 CN CN201680047154.3A patent/CN108026519A/zh active Pending
- 2016-06-16 AU AU2016278226A patent/AU2016278226B2/en active Active
- 2016-06-16 PT PT167338136T patent/PT3310909T/pt unknown
- 2016-06-16 KR KR1020187001436A patent/KR102637402B1/ko active Active
- 2016-06-16 WO PCT/US2016/037922 patent/WO2016205554A1/en not_active Ceased
- 2016-06-16 EP EP21177979.8A patent/EP3929286A1/en active Pending
-
2021
- 2021-05-10 JP JP2021079698A patent/JP7170090B2/ja active Active
- 2021-08-31 JP JP2021141109A patent/JP2021182942A/ja not_active Withdrawn
- 2021-10-18 AU AU2021250992A patent/AU2021250992B2/en active Active
-
2022
- 2022-08-25 US US17/822,240 patent/US20230257737A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016205554A1 (en) | 2016-12-22 |
| JP2018521689A (ja) | 2018-08-09 |
| ES2886599T3 (es) | 2021-12-20 |
| JP7170090B2 (ja) | 2022-11-11 |
| JP2021112211A (ja) | 2021-08-05 |
| AU2016278226A1 (en) | 2018-01-25 |
| US20180187185A1 (en) | 2018-07-05 |
| EP3310909A1 (en) | 2018-04-25 |
| US11473082B2 (en) | 2022-10-18 |
| CA2989827C (en) | 2024-09-10 |
| AU2021250992A1 (en) | 2021-11-11 |
| CA2989827A1 (en) | 2016-12-22 |
| AU2016278226B2 (en) | 2021-08-12 |
| AU2021250992B2 (en) | 2023-09-28 |
| KR20180036696A (ko) | 2018-04-09 |
| EP3310909B1 (en) | 2021-06-09 |
| JP2021182942A (ja) | 2021-12-02 |
| KR102637402B1 (ko) | 2024-02-15 |
| CN108026519A (zh) | 2018-05-11 |
| US20230257737A1 (en) | 2023-08-17 |
| EP3929286A1 (en) | 2021-12-29 |
| HK1253508A1 (zh) | 2019-06-21 |
| DK3310909T3 (da) | 2021-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3310909T (pt) | Composições e métodos para dirigir proteínas para loci específicos no genoma | |
| IL259795A (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| BR112017008877A2 (pt) | métodos e composições para sequenciamento de ácido nucleico-alvo | |
| IL258688A (en) | Compositions and methods for viral cancer neoepitopes | |
| HUE055942T2 (hu) | LPA génexpressziójának gátlására szolgáló készítmények és eljárások | |
| BR112017024747A2 (pt) | composições e métodos para enriquecer populações de ácidos nucleicos | |
| EP3160959C0 (en) | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | |
| DK3390632T3 (da) | Fremgangsmåder og sammensætninger til polymerase ii (pol-ii)-baseret guide-rna-ekspression | |
| KR20180084891A (ko) | 구조 조성물 및 방법 | |
| PT3355990T (pt) | Compostos semifluorados e as suas composições | |
| DK3307872T3 (da) | Fremgangsmåder og sammensætninger til effektiv indgivelse af nukleinsyrer og rna-baserede antimikrober | |
| PL3386534T3 (pl) | Kompozycje i sposoby internalizacji enzymów | |
| EP3313989C0 (en) | MODIFIED CRISPR RNA AND MODIFIED SINGLE CRISPR RNA AND USES THEREOF | |
| DK3234134T3 (da) | Målrettet rna-redigering | |
| DK3274430T3 (da) | Mikroalgesammensætninger og deres anvendelser | |
| EP3337895A4 (en) | REINFORCED RECOMBINATION GENOMIC LOCI | |
| IL257784A (en) | Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition | |
| EP3339331A4 (en) | COMPOSITION | |
| EP3398996A4 (en) | COMPOSITION | |
| DK3182985T3 (da) | Fibroinafledt proteinsammensætning | |
| DK3209323T3 (da) | Forbedret koaguleringssammensætning | |
| IL256322A (en) | Improved formulations of deferasirox and methods of making the same | |
| BR112018000054A2 (pt) | composições farmacêuticas liofilizadas | |
| KR20180084853A (ko) | 지혈 조성물 | |
| EP3560512A4 (en) | COMPOSITION OF VACCINE AGAINST ZONA |